What Do Most HAE Patients Want From Treatment? Fewer Attacks, Survey Finds

What Do Most HAE Patients Want From Treatment? Fewer Attacks, Survey Finds
1.4
(14)

The vast majority of people with hereditary angioedema (HAE) stress the importance of their preventative therapy correcting C1 inhibitor protein deficiency, allowing for fewer attacks, as the leading factor in evaluating a prophylactic treatment, according to a survey by The Harris Poll.

Safety considerations followed closely in importance.

The online survey, sponsored by CSL Behring, engaged 100 adults with HAE along with 150 licensed allergists and immunologists in the U.S. who have treated at least two people living with HAE in the 12 months before the survey. 

A total of 91% of the physicians also agree that fewer attacks and safety are the most critical factors when prescribing prophylactic therapy. However, 72% of patients strongly agree that convenience in treatment — like fewer injections — is of lesser importance than fewer attacks, while 28% of physicians express similar views.

“This data shows that those living with HAE [94%] and their physicians place importance on preventing more attacks, with most people living with HAE preferring a prophylactic treatment that is effective in reducing the number of attacks rather than a treatment that offers less frequent administration,” Jonathan Bernstein, MD, at the University of Cincinnati College of Medicine, said in a press release

“A treatment that may offer less frequent administration may seem appealing, but these findings suggest that many people living with HAE live with daily fear, stress, and anxiety related to having an attack,” he added.

HAE is mostly caused by a deficiency in C1 inhibitor, a protein in the blood that helps control swelling, its hallmark symptom. CSL makes two HAE therapies, Haegarda and Berinert, both of which are solutions of the missing C1 inhibitor protein. 

Berinert is administered intravenously (into-the-vein) during acute symptomatic attacks, while Haegarda aims to prevent attacks by regular subcutaneous (under-the-skin) injection.

According to the survey, 43% of HAE patients say the disease has a major negative impact on every aspect of their lives, whereas 9% of physicians say the same about their patients. Furthermore, 68% of patients think living with HAE has a major or moderate impact on their work or studies.

“HAE affects my life daily; with the concerns and stress of not only maintaining my own health as a patient but also that of my children, both of whom also have HAE,” said Cheryl French.

Other questions regarding the impact of HAE on lifestyle found 76% of HAE patients worry about having another attack every day, and over 80% consider recovering from an attack to be disruptive to their quality of life.

A total of 70% of people with HAE rate their attacks as severe or very severe, and only 35% think their HAE is very well controlled.

Concerning treatment, more than 95% of patients say they will take whatever measures are necessary to avoid attacks, and 82% of physicians agree. Moreover, 97% of people with HAE, and 99% of physicians agree that preventing attacks is the best way to manage HAE. 

These findings demonstrate that HAE patients and their physicians are generally aligned when it comes to treatment choices. Still, the results also found that patients and clinicians may benefit from a better understanding of mutual priorities in selecting a therapy, the company said. 

“These substantial burdens should be important points of consideration when discussing and developing treatment plans,” Bernstein said.

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Total Posts: 16
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Latest Posts
  • PHA121
  • Haegarda older patients

How useful was this post?

Click on a star to rate it!

Average rating 1.4 / 5. Vote count: 14

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?